

July 31, 2025

# Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada" or the "Company"), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress.

## Conference Call and Webcast Information:

- Date: Thursday, August 7, 2025 at 4:30 PM ET
- Participant Dial-in (US): 1-877-407-0792
- Participant Dial-in (International): 1-201-689-8263
- Conference: 13754263
- Webcast Access: [Click Here](#)

A replay of the webcast will be available in the Investors section of the Relmada website at <https://www.relmada.com/investors/ir-calendar>.

## About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology-related and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit [www.relmada.com](http://www.relmada.com)

## Investor Contact:

Brian Ritchie  
LifeSci Advisors  
[britchie@lifesciadvisors.com](mailto:britchier@lifesciadvisors.com)

## Media Inquiries:

Corporate Communications  
[media@relmada.com](mailto:media@relmada.com)



Source: Relmada Therapeutics

